Aviceda announces successful submission of an investigational new drug (ind) and fast track designation (ftd) application for avd-104 for the treatment of geographic atrophy associated with age-related macular degeneration (amd)

Cambridge, mass.--(business wire)--aviceda therapeutics, a private biotech company focused on developing the next generation immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic, non-resolving inflammation, today announced that it has submitted an investigational new drug (ind) application to the u.s. food and drug administration (fda).
AMD Ratings Summary
AMD Quant Ranking